Global CRISPR and CRISPR-Associated (Cas) Genes Market Analysis and Forecast 2026-2032
Description
This report studies the CRISPR And CRISPR-Associated (Cas) Genes market.
Clustered regularly interspaced short palindromic repeats (CRISPR) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of spacer DNA from previous exposures to a bacteriophage virus or plasmid.
The CRISPR/Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages, and provides a form of acquired immunity. CRISPR associated proteins (Cas) use the CRISPR spacers to recognize and cut these exogenous genetic elements in a manner analogous to RNA interference in eukaryotic organisms. CRISPRs are found in approximately 40% of sequenced bacterial genomes and 90% of sequenced archaea.
Cas9 was the first nuclease discovered, followed by Cpf1, which was discovered in the CRISPR/Cpf1 system of Francisella novicida. Other such systems are thought to exist. CRISPR/Editas Medicinec2 from the bacterium Leptotrichia shahii is RNA-guided CRISPR system that targets RNA rather than DNA, and can either cleave single-stranded RNA targets or knock them down.
By delivering the Cas9 nuclease complexed with a synthetic guide RNA (gRNA) into a cell, the cell's genome can be cut at a desired location, allowing existing genes to be removed and/or new ones added. The Cas9-gRNA complex corresponds with the CAS III crRNA complex in the above diagram. CRISPR/Cas genome editing techniques have many potential applications, including altering the germline of humans, animals, and food crops. The use of CRISPR Cas9-gRNA complex for genome editing was the AAAS's choice for breakthrough of the year in 2015. Bioethical concerns have been expressed about the prospect of using this nascent biotechnology for editing the human germline.
Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR therapeutics and Intellia therapeutics, Inc. are the top 5 players of CRISPR and CRISPR-Associated (Cas) Genes, with about 63% market shares.
CRISPR And CRISPR-Associated (Cas) Genes industry is relatively concentrated, manufacturers are mostly in the Europe and North America. Among them, North America region accounted for more than 45% of the total market of global CRISPR And CRISPR-Associated (Cas) Genes.
Report Includes
This report presents an overview of global market for CRISPR and CRISPR-Associated (Cas) Genes, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of CRISPR and CRISPR-Associated (Cas) Genes, also provides the revenue of main regions and countries. Of the upcoming market potential for CRISPR and CRISPR-Associated (Cas) Genes, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the CRISPR and CRISPR-Associated (Cas) Genes revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global CRISPR and CRISPR-Associated (Cas) Genes market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for CRISPR and CRISPR-Associated (Cas) Genes revenue, projected growth trends, production technology, application and end-user industry.
CRISPR and CRISPR-Associated (Cas) Genes Segment by Company
Thermo Fisher Scientific
Editas Medicine
Caribou Biosciences
CRISPR therapeutics
Intellia therapeutics, Inc.
Cellectis
Horizon Discovery Plc
Sigma Aldrich
Precision Biosciences
Genscript
Sangamo Biosciences Inc.
Lonza Group Limited
Integrated DNA Technologies
New England Biolabs
Origene Technologies
CRISPR and CRISPR-Associated (Cas) Genes Segment by Type
Genome Editing
Genetic engineering
gRNA Database/Gene Librar
CRISPR Plasmid
Human Stem Cells
Genetically Modified Organisms/Crops
Cell Line Engineering
CRISPR and CRISPR-Associated (Cas) Genes Segment by Application
Biotechnology Companies
Pharmaceutical Companies
Academic Institutes
Research and Development Institutes
CRISPR and CRISPR-Associated (Cas) Genes Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CRISPR and CRISPR-Associated (Cas) Genes market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CRISPR and CRISPR-Associated (Cas) Genes and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CRISPR and CRISPR-Associated (Cas) Genes.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of CRISPR and CRISPR-Associated (Cas) Genes in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of CRISPR and CRISPR-Associated (Cas) Genes company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, CRISPR and CRISPR-Associated (Cas) Genes revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Clustered regularly interspaced short palindromic repeats (CRISPR) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of spacer DNA from previous exposures to a bacteriophage virus or plasmid.
The CRISPR/Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages, and provides a form of acquired immunity. CRISPR associated proteins (Cas) use the CRISPR spacers to recognize and cut these exogenous genetic elements in a manner analogous to RNA interference in eukaryotic organisms. CRISPRs are found in approximately 40% of sequenced bacterial genomes and 90% of sequenced archaea.
Cas9 was the first nuclease discovered, followed by Cpf1, which was discovered in the CRISPR/Cpf1 system of Francisella novicida. Other such systems are thought to exist. CRISPR/Editas Medicinec2 from the bacterium Leptotrichia shahii is RNA-guided CRISPR system that targets RNA rather than DNA, and can either cleave single-stranded RNA targets or knock them down.
By delivering the Cas9 nuclease complexed with a synthetic guide RNA (gRNA) into a cell, the cell's genome can be cut at a desired location, allowing existing genes to be removed and/or new ones added. The Cas9-gRNA complex corresponds with the CAS III crRNA complex in the above diagram. CRISPR/Cas genome editing techniques have many potential applications, including altering the germline of humans, animals, and food crops. The use of CRISPR Cas9-gRNA complex for genome editing was the AAAS's choice for breakthrough of the year in 2015. Bioethical concerns have been expressed about the prospect of using this nascent biotechnology for editing the human germline.
Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR therapeutics and Intellia therapeutics, Inc. are the top 5 players of CRISPR and CRISPR-Associated (Cas) Genes, with about 63% market shares.
CRISPR And CRISPR-Associated (Cas) Genes industry is relatively concentrated, manufacturers are mostly in the Europe and North America. Among them, North America region accounted for more than 45% of the total market of global CRISPR And CRISPR-Associated (Cas) Genes.
Report Includes
This report presents an overview of global market for CRISPR and CRISPR-Associated (Cas) Genes, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of CRISPR and CRISPR-Associated (Cas) Genes, also provides the revenue of main regions and countries. Of the upcoming market potential for CRISPR and CRISPR-Associated (Cas) Genes, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the CRISPR and CRISPR-Associated (Cas) Genes revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global CRISPR and CRISPR-Associated (Cas) Genes market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for CRISPR and CRISPR-Associated (Cas) Genes revenue, projected growth trends, production technology, application and end-user industry.
CRISPR and CRISPR-Associated (Cas) Genes Segment by Company
Thermo Fisher Scientific
Editas Medicine
Caribou Biosciences
CRISPR therapeutics
Intellia therapeutics, Inc.
Cellectis
Horizon Discovery Plc
Sigma Aldrich
Precision Biosciences
Genscript
Sangamo Biosciences Inc.
Lonza Group Limited
Integrated DNA Technologies
New England Biolabs
Origene Technologies
CRISPR and CRISPR-Associated (Cas) Genes Segment by Type
Genome Editing
Genetic engineering
gRNA Database/Gene Librar
CRISPR Plasmid
Human Stem Cells
Genetically Modified Organisms/Crops
Cell Line Engineering
CRISPR and CRISPR-Associated (Cas) Genes Segment by Application
Biotechnology Companies
Pharmaceutical Companies
Academic Institutes
Research and Development Institutes
CRISPR and CRISPR-Associated (Cas) Genes Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CRISPR and CRISPR-Associated (Cas) Genes market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CRISPR and CRISPR-Associated (Cas) Genes and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CRISPR and CRISPR-Associated (Cas) Genes.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of CRISPR and CRISPR-Associated (Cas) Genes in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of CRISPR and CRISPR-Associated (Cas) Genes company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, CRISPR and CRISPR-Associated (Cas) Genes revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
193 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 CRISPR and CRISPR-Associated (Cas) Genes Market by Type
- 1.2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Genome Editing
- 1.2.3 Genetic engineering
- 1.2.4 gRNA Database/Gene Librar
- 1.2.5 CRISPR Plasmid
- 1.2.6 Human Stem Cells
- 1.2.7 Genetically Modified Organisms/Crops
- 1.2.8 Cell Line Engineering
- 1.3 CRISPR and CRISPR-Associated (Cas) Genes Market by Application
- 1.3.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Biotechnology Companies
- 1.3.3 Pharmaceutical Companies
- 1.3.4 Academic Institutes
- 1.3.5 Research and Development Institutes
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
- 2 CRISPR and CRISPR-Associated (Cas) Genes Market Dynamics
- 2.1 CRISPR and CRISPR-Associated (Cas) Genes Industry Trends
- 2.2 CRISPR and CRISPR-Associated (Cas) Genes Industry Drivers
- 2.3 CRISPR and CRISPR-Associated (Cas) Genes Industry Opportunities and Challenges
- 2.4 CRISPR and CRISPR-Associated (Cas) Genes Industry Restraints
- 3 Global Growth Perspective
- 3.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market Perspective (2021-2032)
- 3.2 Global CRISPR and CRISPR-Associated (Cas) Genes Growth Trends by Region
- 3.2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Region (2021-2026)
- 3.2.3 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Region (2027-2032)
- 4 Competitive Landscape by Players
- 4.1 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Players
- 4.1.1 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Players (2021-2026)
- 4.1.2 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Players (2021-2026)
- 4.1.3 Global CRISPR and CRISPR-Associated (Cas) Genes Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global CRISPR and CRISPR-Associated (Cas) Genes Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global CRISPR and CRISPR-Associated (Cas) Genes Key Players Headquarters & Area Served
- 4.4 Global CRISPR and CRISPR-Associated (Cas) Genes Players, Product Type & Application
- 4.5 Global CRISPR and CRISPR-Associated (Cas) Genes Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market CR5 and HHI
- 4.6.3 2025 CRISPR and CRISPR-Associated (Cas) Genes Tier 1, Tier 2, and Tier 3
- 5 CRISPR and CRISPR-Associated (Cas) Genes Market Size by Type
- 5.1 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021-2032)
- 5.3 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Type (2021-2032)
- 6 CRISPR and CRISPR-Associated (Cas) Genes Market Size by Application
- 6.1 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021-2032)
- 6.3 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Application (2021-2032)
- 7 Company Profiles
- 7.1 Thermo Fisher Scientific
- 7.1.1 Thermo Fisher Scientific Company Information
- 7.1.2 Thermo Fisher Scientific Business Overview
- 7.1.3 Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
- 7.1.4 Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 7.1.5 Thermo Fisher Scientific Recent Developments
- 7.2 Editas Medicine
- 7.2.1 Editas Medicine Company Information
- 7.2.2 Editas Medicine Business Overview
- 7.2.3 Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
- 7.2.4 Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 7.2.5 Editas Medicine Recent Developments
- 7.3 Caribou Biosciences
- 7.3.1 Caribou Biosciences Company Information
- 7.3.2 Caribou Biosciences Business Overview
- 7.3.3 Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
- 7.3.4 Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 7.3.5 Caribou Biosciences Recent Developments
- 7.4 CRISPR therapeutics
- 7.4.1 CRISPR therapeutics Company Information
- 7.4.2 CRISPR therapeutics Business Overview
- 7.4.3 CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
- 7.4.4 CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 7.4.5 CRISPR therapeutics Recent Developments
- 7.5 Intellia therapeutics, Inc.
- 7.5.1 Intellia therapeutics, Inc. Company Information
- 7.5.2 Intellia therapeutics, Inc. Business Overview
- 7.5.3 Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
- 7.5.4 Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 7.5.5 Intellia therapeutics, Inc. Recent Developments
- 7.6 Cellectis
- 7.6.1 Cellectis Company Information
- 7.6.2 Cellectis Business Overview
- 7.6.3 Cellectis CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
- 7.6.4 Cellectis CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 7.6.5 Cellectis Recent Developments
- 7.7 Horizon Discovery Plc
- 7.7.1 Horizon Discovery Plc Company Information
- 7.7.2 Horizon Discovery Plc Business Overview
- 7.7.3 Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
- 7.7.4 Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 7.7.5 Horizon Discovery Plc Recent Developments
- 7.8 Sigma Aldrich
- 7.8.1 Sigma Aldrich Company Information
- 7.8.2 Sigma Aldrich Business Overview
- 7.8.3 Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
- 7.8.4 Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 7.8.5 Sigma Aldrich Recent Developments
- 7.9 Precision Biosciences
- 7.9.1 Precision Biosciences Company Information
- 7.9.2 Precision Biosciences Business Overview
- 7.9.3 Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
- 7.9.4 Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 7.9.5 Precision Biosciences Recent Developments
- 7.10 Genscript
- 7.10.1 Genscript Company Information
- 7.10.2 Genscript Business Overview
- 7.10.3 Genscript CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
- 7.10.4 Genscript CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 7.10.5 Genscript Recent Developments
- 7.11 Sangamo Biosciences Inc.
- 7.11.1 Sangamo Biosciences Inc. Company Information
- 7.11.2 Sangamo Biosciences Inc. Business Overview
- 7.11.3 Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
- 7.11.4 Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 7.11.5 Sangamo Biosciences Inc. Recent Developments
- 7.12 Lonza Group Limited
- 7.12.1 Lonza Group Limited Company Information
- 7.12.2 Lonza Group Limited Business Overview
- 7.12.3 Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
- 7.12.4 Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 7.12.5 Lonza Group Limited Recent Developments
- 7.13 Integrated DNA Technologies
- 7.13.1 Integrated DNA Technologies Company Information
- 7.13.2 Integrated DNA Technologies Business Overview
- 7.13.3 Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
- 7.13.4 Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 7.13.5 Integrated DNA Technologies Recent Developments
- 7.14 New England Biolabs
- 7.14.1 New England Biolabs Company Information
- 7.14.2 New England Biolabs Business Overview
- 7.14.3 New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
- 7.14.4 New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 7.14.5 New England Biolabs Recent Developments
- 7.15 Origene Technologies
- 7.15.1 Origene Technologies Company Information
- 7.15.2 Origene Technologies Business Overview
- 7.15.3 Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
- 7.15.4 Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 7.15.5 Origene Technologies Recent Developments
- 8 North America
- 8.1 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue (2021-2032)
- 8.2 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021-2032)
- 8.2.1 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021-2026)
- 8.2.2 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2027-2032)
- 8.3 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2021-2032)
- 8.4 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021-2032)
- 8.4.1 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021-2026)
- 8.4.2 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2027-2032)
- 8.5 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2021-2032)
- 8.6 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country
- 8.6.1 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2021-2026)
- 8.6.3 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
- 9 Europe
- 9.1 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue (2021-2032)
- 9.2 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021-2032)
- 9.2.1 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021-2026)
- 9.2.2 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2027-2032)
- 9.3 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2021-2032)
- 9.4 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021-2032)
- 9.4.1 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021-2026)
- 9.4.2 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2027-2032)
- 9.5 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2021-2032)
- 9.6 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country
- 9.6.1 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2021-2026)
- 9.6.3 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
- 10 China
- 10.1 China CRISPR and CRISPR-Associated (Cas) Genes Revenue (2021-2032)
- 10.2 China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021-2032)
- 10.2.1 China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021-2026)
- 10.2.2 China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2027-2032)
- 10.3 China CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2021-2032)
- 10.4 China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021-2032)
- 10.4.1 China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021-2026)
- 10.4.2 China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2027-2032)
- 10.5 China CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2021-2032)
- 11 Asia (Excluding China)
- 11.1 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue (2021-2032)
- 11.2 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021-2032)
- 11.2.1 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021-2026)
- 11.2.2 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2027-2032)
- 11.3 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2021-2032)
- 11.4 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021-2032)
- 11.4.1 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021-2026)
- 11.4.2 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2027-2032)
- 11.5 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2021-2032)
- 11.6 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country
- 11.6.1 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2021-2026)
- 11.6.3 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
- 12 South America, Middle East and Africa
- 12.1 SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue (2021-2032)
- 12.2 SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021-2032)
- 12.2.1 SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021-2026)
- 12.2.2 SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2027-2032)
- 12.3 SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2021-2032)
- 12.4 SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021-2032)
- 12.4.1 SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021-2026)
- 12.4.2 SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2027-2032)
- 12.5 SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2021-2032)
- 12.6 SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country
- 12.6.1 SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2021-2026)
- 12.6.3 SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
- 13 Concluding Insights
- 14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

